Therapeutic pyrazoloquinoline derivatives

Details Therapeutic pyrazoloquinoline derivatives Therapeutic pyrazoloquinoline derivatives

2011-01-18

2011-01-18

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S231800, C514S232200, C514S232800, C514S252110, C514S315000, C514S320000, C540S575000, C544S126000, C544S361000, C546S082000

Reexamination Certificate

active

07872002

ABSTRACT:
The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAAreceptor and modulating GABAA, and use of the compound of formula I for the treatment of GABAAreceptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms:The invention further provides a method of modulation of one or more GABAAsubtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

REFERENCES:
patent: 4552874 (1985-11-01), Mardin et al.
patent: 4690930 (1987-09-01), Takada et al.
patent: 4814450 (1989-03-01), Yokoyama
patent: 5334595 (1994-08-01), Wentland
patent: 6686373 (2004-02-01), Kawamura et al.
patent: 2005/0004159 (2005-01-01), Hibi et al.
patent: 2005/0245563 (2005-11-01), Boyle et al.
patent: 2006/0035919 (2006-02-01), Matthews et al.
patent: 2006/0100229 (2006-05-01), Hays et al.
patent: 2007/0078083 (2007-04-01), Barlow et al.
patent: 0 214 092 (1986-08-01), None
patent: WO 99/06401 (1999-02-01), None
Atack et al., “The proconvulsant effects of the GABAAα5 subtype-selective compound RY-080 may not be α5-mediated”, European Journal of Pharmacology, 548:77-82 (2006).
Barnard et al., “International Union of Pharmacology. XV. Subtypes of γ-Aminobutyric AcidAReceptors: Classification on the Basis of Subunit Structure and Receptor Function” Pharmacol. Rev. 50(2):291-313 (1998).
Low et al., “Molecular and Neuronal Substrate for the Selective Attenuation of Anxiety”, Science, 290:131-134 (2000).
McKernan et al., “Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAAreceptor α1subtype”, Nat. Neurosci. 3:587-592 (2000).
Muller, “New trends in benzodiazepine research”, Drugs of Today, 24:649-663 (1988).
Rudolph et al., “Benzodiazepine actions mediated by specific α-aminobutyric acidAreceptor subtypes”, Nature, 401:796-800 (1999).
Takada et al., “Thienylpyrazoloquinolines: Potent Agonists and Inverse Agonists to Benzodiazepine Receptors”, J. Med. Chem., 31:1738-1745 (1988).
Yokoyama et al., “2-Arylpyrazolo[4,3-c]quinolin-3-ones: Novel agonist, Partial Agonist and Antagonist of Benzodiazepines” J. Med. Chem., 25:337-339 (1982).
International Search Report for corresponding PCT Application No. PCT/US08/66201 mailed Oct. 7, 2008.
International Written Opinion for corresponding PCT Application No. PCT/US08/66201 mailed Oct. 7, 2008.
Allen et al., “Synthesis of novel 2-Phenyl-2H-pyrazolo[4,3-c]isoquinolin-3-ols: Topological Comparisons with Analogues of 2-Phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones at benzodiazepine receptors,”J. Med. Chem., 1992, 35(2): 368-374.
Carotti et al., “High Affinity Central Benzodiazepine Receptor Ligands. Part 3: Insights Into the Pharmacophore and Pattern Recognition Study of Intrinsic Activities of Pyrazole[4,3-c]quinolin-3-ones,” Bioorg. & Med. Chem., 2003, 11(23): 5259-5272.
Fryer et al., “Structure Activity Relationships of 2-Phenylpyrazolo[4,3-c]quinolin-3-ones and their N- and O-Methyl Analogs at Benzodiazepine Receptors,”Med. Chem. Res., 1993, 3: 122-130.
Lister et al., “A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat,”Psychopharmacology, 1984, 84: 420-422.
Jacobsen et al., “Piperazine imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABAALigands of Dual Functionality”,J. Med. Chem., 1999, 42(7): 1123-1144.
Allen et al., “Synthesis of novel 2-Phenyl-2H-pyrazolo[4,3-c]isoquinolin-3-ols: Topological Comparisons with Analogues of 2-Phenyl-2,5-dihydropyrazolo[4,3-c]quinolin-3(3H)-ones at benzodiazepine receptors,”J. Med. Chem., 1992, 35(2): 368-374.
Carotti et al., “High Affinity Central Benzodiazepine Receptor Ligands. Part 3: Insights Into the Pharmacophore And Pattern Recognition Study of Intrinsic Activities of Pyrazole[4,3-c]quinolin-3-ones,” Bioorg. & Med. Chem., 2003, 11(23): 5259-5272.
Fryer et al., “Structure Activity Relationships of 2-Phenylpyrazolo[4,3-c]quinolin-3-ones and their N- and O-Methyl Analogs at Benzodiazepine Receptors,”Med. Chem. Res., 1993, 3: 122-130.
Lister et al., “A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat,”Psychopharmacology, 1984, 84: 420-422.

Affiliated with

Also associated with

Rating

Therapeutic pyrazoloquinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic pyrazoloquinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic pyrazoloquinoline derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2705190